Prof. S. Shakir Jamil

1
Role of Unani Medicine as Adjuvant therapy in
Chronic Incurable Diseases

• Prof. S. Shakir Jamil
• Director General
• CCRUM, Department of AYUSH
• New Delhi

10th Knowledge Millenium Summit-2013 Curing the
Incurables Sharing of Innovation 16th January,
2013, Vigyan Bhavan, New Delhi
2
Origin Caravan

• Unani System of Medicine originated from Greece
• The philosophical doctrines of the System was
  laid down by Hippocrates. (460-377 BC)
• Arab, Central Asian and European countries
  contributed to the system.
• From Central Asia Unani Medicine traversed to
  India

3
Present Scenario

• Today, India is the world leader in Unani
  Medicine having largest set up of educational,
  healthcare and research facilities.
• Unani medicine is also recognized, practiced and
  popular in Pakistan, Bangladesh, Malaysia, Sri
  Lanka and South Africa.
• Also Practiced in Kuwait, Dubai Saudi Arabia
  etc.

4
Fundamental concepts

• Tabiyat (Medicatrix naturae)
• Mizaj (Temperament)
• Akhlat (Body Humours)
• Usool-e- Ijaj (Principles of treatment) including
  Ilaj-bit-Tadbir (Regimenal Therapy)

5
Research Development

• CCRUM
• Central Council for Research in Unani Medicine
  (CCRUM) was established by Government of India as
  apex organization for Research and Development
  activities in Unani System of Medicine in 1979.
• The Council is an autonomous organization under
  Department of AYUSH, Ministry of Health Family
  Welfare, Govt of India.

6
(No Transcript)
7
Central Council for Research in Unani Medicine
8
CCRUM - Mandate

• Research in Unani Medicine on scientific lines.
• To initiate, aid, develop and coordinate
  scientific research of Unani Medicine.
• To finance researches meant for furtherance of
  objective of the CCRUM.
• To exchange information with other institutions.
• To prepare and publish literature on Unani
  medicine.

8
9

• Research Programmes
• Pre-clinical/Safety Studies
• Clinical Research
• Fundamental aspects of Unani Medicine
• Drug Standardization including SOPs for Unani
  drugs
• Literature including Medico-historical Research
• Ethno-botanical Survey, Collection and
  Cultivation of Unani Medicinal Plants
• IEC and other Research oriented programmes

10
Pre-Clinical Clinical Research

• Pharmacological action/safety evaluation 22 drugs
• Number of diseases clinically studied 22
• Clinical trials completed 13 drugs
• Number of drugs under trial 30

11
Validation of Pharmacopoeal drugs

• Validation of safety efficacy of Unani
  pharmacopoeial
• Drugs.
• Number of formulations 25
• Number of diseases under study 10

12
Leads in Clinical Research

• Bars (Vitiligo)
• Naar-e- Farsi (Eczema)
• Taqashshur-e-Jild (Psoriasis )
• Zeequn-Nafas (Bronchial asthma )
• Zaght-ud- Dam Qawi (Hypertension)
• Daa-ul-Feel (Filariasis)
• Iltehaab-e-Mafasil (Rheumatoid arthritis)
• Iltehaab-e-Tajaweef-e-Aanaf (Sinusitis)

13
Validation of Unani Fundamentals

• Study on susceptibility of acquiring diseases in
  relation to
• Mizaj (temperament).
• Study on molecular interpretation of individual
  
• temperament at CRIUM, Hyderabad
• in collaboration
• with Center for Cellular and Molecular Biology,
  CSIR, Hyderabad.

14
Drug Standardization including SOPs for Unani
drugs
Unani single drugs standardized 298
SOPs developed for compound Unani
formulations 100
15
Patents
Patents awarded 08
drugs Patents filed 41 drugs
16

• Literary Research

Translation of classical books/manuscripts in different languages. 51
Books/brochures/leaflets and IEC material in different languages. 25
Reprint of rare classical books 88
Standardization of Unani Terminology 4000 terms
17
Collaboration/support with other institutions

• All India Institute of Medical Sciences, (AIIMS)
  New Delhi.
• Vallabh Bhai Patel Chest Institute, University of
  Delhi, New Delhi.
• Jamia Hamdard (Hamdard University), New Delhi.
• KGMC, Lucknow.
• Ibn-e-Sina Academy, Aligarh.
• Centre of Liver diseases Deccan Med. College,
  Hyderabad
• Taramani Hospital Res. Centre, Chennai.
• Osmania General Hospital Hyderabad.

18
Contd.. Collaboration/support with other
institutions

• With the financial support by DST for creating
  research infra-structure two facilities were
  created
• Clinical Research facilitiy at CRI, Hyderabad.
• Pre-clinical research facilitiy at RRI, Srinagar.

19
Collaboration with Foreign Institutions

• Centre for Research in Indian Systems of Medicine
  (CRISM) in University of Mississippi, USA
• UNANI CHAIR at University of Western Cape, South
  Africa
• UNANI CHAIR at Sri Lanka is in process

20
Unani Medicine as Adjuvant therapy

• Thrust areas
• Immuno-modulation
• To prevent drug toxicity
• To improve Quality of Life

21
Contd..
Unani Medicine as Adjuvant therapy

• Areas
• Cognitive impairment
• Tuberculosis (especially MDR TB)
• Cancer
• HIV / AIDS

22
Unani Medicine as Adjuvant therapy
Contd..

• Study 1
• Cognitive impairment
• Title
• Evaluation of a Unani Formulation for Improving
  Cognitive Impairment in Children with Cerebral
  Palsy and Mental Retardation
• The study was conducted at Majeedia Hospital,
  Jamia Hamdard in collaboration with UDAAN an NGO
  working for disabled children.
• This was a controlled study in which both
  groups were given physiotherapy and special
  education but one group was given Unani
  formulation and other group HBOT.
• The study was conducted on current clinical
  parameters following the GCP.
• Objective
• To prove efficacy of Unani formulation in the
  treatment of Neurodevelopmental disabilities with
  special emphases on cognitive improvement in
  Cerebral Palsy (C.P.) and/or Mental Retardation
  (M.R.).
• Outcome
• Long term amelioration of associated behavioural
  and neurological
  problems
• Improvement in memory and cognitive functions
• Improvement in musculo-skeletal deformities

23
Unani Medicine as Adjuvant therapy
Contd

• Study 2
• Title
• Study on management of Pulmonary Tuberculosis
  with herbal Unani product (0394) as an adjuvant
  drug .
• The study was sponsored by Panacea Biotech and
  conducted at Majeedia Hospital, Jamia Hamdard,
  Hamdard Nagar, New Delhi.
• This was a controlled study in which ATT was
  given to both groups and only one group was
  given Unani adjuvant formulation along with ATT.
• The study was conducted on current clinical
  parameters following the GCP.
• Objective
• To evaluate the efficacy of Unani formulation in
  enhancement of resolution rate in Pulmonary
  Tuberculosis including MDR.
• Outcome
• Fast resolution of infiltration in chest.
• Faster sputum clearance for AFB.
• Better response in MDR cases.

24
Contd
Unani Medicine as Adjuvant therapy

• Study 3
• Title
• Clinical evaluation of a Unani formulation for
  prevention ofhepato-nephro toxicity in Pulmonary
  Tuberculosis.
• (The study was conducted at Majeedia Hospital,
  Jamia Hamdard.
• This was a controlled study in which both groups
  were given ATT and one group was Unani
  Hepato-protective formulation.
• The study was conducted on current clinical
  parameters following the GCP.
• Objective
• To evaluate efficacy of Unani formulation in the
  treatment of Pulmonary Tuberculosis with
  reference to prevention of hepato-nephro
  toxicity.

25
Contd
Unani Medicine as Adjuvant therapy

• Cancer
• Objective of the study is to prevent the
  hepato-nephro toxicity during chemotherapy and to
  improve the Quality of Life in Cancer patients.
• Feasibility study has been completed. Detailed
  planning and protocol designing at CRIUM, Lucknow
  is under progress.

26
Contd
Unani Medicine as Adjuvant therapy

• HIV / AIDS
• Objective of the study is to improve, enhance and
  potentiate body immunity and to improve the
  Quality of Life in HIV/AIDS patients.
• Feasibility study has been conducted. Detailed
  planning and protocol designing at RRIUM, Mumbai
  in collaboration with J.J. Hospital, Mumbai.

27
Thank You